Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis.

StrokeSep 3, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Xiaohui Zi, Yong He, Guojuan Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This subgroup analysis of the TAPIS trial evaluated the impact of diffusion-weighted imaging infarction patterns on the efficacy and safety of ticagrelor-aspirin combined with thrombolysis in 1307 patients with moderate acute ischemic stroke. The study found that ticagrelor-aspirin improved outcomes in patients with multiple acute infarcts (MAIs) compared to placebo (64.4% vs 53.4%).

Key findings

  • MAIs were linked to poorer prognosis than non-MAIs (58.9% vs 69.2% excellent outcome).
  • Ticagrelor-aspirin showed a higher likelihood of excellent outcomes in MAIs (64.4% vs 53.4%).
  • No significant benefit of ticagrelor-aspirin was observed in non-MAIs (71.2% vs 67.1%).
  • Symptomatic intracranial hemorrhage rates were low and similar across groups.

Why it matters

Understanding how infarction patterns affect treatment outcomes can help clinicians tailor antiplatelet therapy in acute ischemic stroke, potentially improving patient prognosis and safety.

Source

PubMed · PMID 42689322

Published in Stroke. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.